Valuation : Celldex Therapeutics, Inc.

Market Cap 3.12B 2.68B 2.52B 2.3B 4.31B 294B 4.33B 29.81B 11.57B 151B 11.7B 11.44B 487B P/E 2026 *
-9.51x
P/E 2027 * -9.46x
Enterprise Value 2.45B 2.11B 1.99B 1.81B 3.4B 232B 3.41B 23.47B 9.11B 119B 9.21B 9.01B 383B EV / Sales 2026 *
1,234x
EV / Sales 2027 * 208x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Celldex Therapeutics, Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.09B
-2.54%-3.60%-0.60%+15.17% 50.35B
-0.40%-5.03%+428.09%+499.20% 45.2B
-1.42%+2.05%+45.04%+19.36% 44.71B
-1.22%-3.82%+6.54%+71.48% 41.24B
+0.53%-1.67%+15.16%+49.88% 33.08B
-0.21%+8.50% - - 17.81B
-0.35%-3.32%+22.87%+116.19% 16.56B
-1.01%-0.38%+15.69%+28.39% 14.82B
-1.65%-2.67%+77.72%+37.63% 14B
Average -0.92%+0.01%+76.31%+104.66% 30.86B
Weighted average by Cap. -1.04%-0.46%+91.57%+121.80%

Financials

2026 *2027 *
Net sales 1.99M 1.71M 1.61M 1.47M 2.75M 188M 2.76M 19.02M 7.38M 96.28M 7.46M 7.3M 311M 11.92M 10.27M 9.64M 8.82M 16.5M 1.13B 16.55M 114M 44.28M 577M 44.76M 43.79M 1.86B
Net income -317M -273M -257M -235M -439M -29.96B -440M -3.03B -1.18B -15.36B -1.19B -1.16B -49.55B -355M -306M -287M -263M -491M -33.55B -493M -3.4B -1.32B -17.2B -1.33B -1.3B -55.48B
Net Debt -662M -570M -536M -490M -916M -62.58B -920M -6.34B -2.46B -32.08B -2.49B -2.43B -103B -638M -549M -516M -472M -882M -60.24B -885M -6.1B -2.37B -30.88B -2.39B -2.34B -99.6B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
39.37USD
Average target price
58.07USD
Spread / Average Target
+47.49%

Quarterly revenue - Rate of surprise